RECOMBINANT MVA VIRUSES FOR INTRAPERITONEAL ADMINISTRATION FOR TREATING CANCER

The invention relates to methods for treating cancer and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen ("TAA") as well as 4-1BBL and/or CD40L and is administered to a subject intraperitoneally.

Saved in:
Bibliographic Details
Main Authors MEDINA ECHEVERZ, José, HAUSMANN, Jürgen, BERRAONDO LÓPEZ, Pedro, HABJAN, Matthias, HINTERBERGER, Maria, KALLA, Markus
Format Patent
LanguageEnglish
French
German
Published 30.10.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to methods for treating cancer and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen ("TAA") as well as 4-1BBL and/or CD40L and is administered to a subject intraperitoneally.
Bibliography:Application Number: EP20220844103